Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe cutaneous adverse reaction to drugs. The disease carries considerable morbidity and mortality.
Immunomodulators for SJS/TEN such as systemic corticosteroids and intravenous immunoglobulin (IVIG) have been widely used in clinical practice.
Emerging evidence suggested that tumor necrosis factor-α antagonists on SJS/TEN may help.
This restrospective review found that add-in of etanercept at the time of initiating conventional therapy could be a superior option to:
- accelerate disease recovery
- reduce the high dose and total amount of systemic steroids
References:
https://www.annallergy.org/article/S1081-1206(22)00441-0/fulltext
https://www.annallergy.org/article/S1081-1206(22)00579-8/fulltext